Essity

Sweden · www.essity.com · 19 vendors

Essity is a global hygiene and health company that develops, produces, and sells products and solutions across personal care, consumer tissue, professional hygiene, and medical solutions. The company's offerings include incontinence products, feminine care, baby care, toilet paper, and medical solutions like wound care and orthopedics. Essity operates in approximately 150 countries worldwide.

Resilience scores

Disruption prediction

Essity has an estimated 11% probability of disruption in the next 6 months.

13 of Essity's 19 vendors monitored for disruptions.

Technology vendors

Services catalogue

1 service in catalogue across 1 category; runs on 19 sub-vendors.

Insights

Last updated 2026-08-11 · revision 7

19 direct vendors, 255 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 4/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

Essity exhibits a medium-to-low level of migration readiness. On the positive side, the company's strong financial stability, with SEK 147.1B in revenue in 2023, provides the necessary capital to fund significant migration initiatives. Essity has already adopted key cloud platforms such as Microsoft Azure, Microsoft 365, and Salesforce, indicating a strategic move towards cloud-based infrastructure and a foundational understanding of cloud operations. The company's investment in IoT, mobile app development, and data analytics also suggests a progressive approach to technology, which can facilitate the adoption of modern, cloud-native architectures. Assuming the presence of vendors (despite the "Total Vendors: 0" data point, which is contradicted by "Total Services: 22" from 6 countries), the geographic diversity of these vendor headquarters could offer some flexibility and reduce single-vendor lock-in, although the specific "Vendor Lock-in Risk" remains "Unknown." However, migration readiness is significantly challenged by an exceptionally complex and high-risk regulatory environment. Essity faces numerous "Assessment Required" and "High Risk" statuses for critical regulations including GDPR, NIS2, EU MDR, CSRD, HIPAA, ISO 27001, US State Privacy Laws, and the Swedish Personal Data Act. Each of these regulations imposes stringent requirements on data processing, security, and reporting, which must be meticulously addressed during any migration. The global data residency requirements, stemming from operations in approximately 150 countries, present a formidable obstacle. Specific mandates for EU/EEA data (GDPR, NIS2, MDR, CSRD), sensitive health data (GDPR Article 9, potential HIPAA in the US), and country-specific localization laws (e.g., Russia, China) necessitate a highly granular and compliant data architecture, making large-scale cloud migrations exceptionally complex and costly. The presence of SAP ERP in the internal tech stack, if it's a legacy on-premise implementation, could also represent a substantial and time-consuming migration challenge. The combination of extensive regulatory and data residency complexities, despite existing cloud adoption and financial capacity, significantly lowers Essity's overall migration readiness.

Compliance

14 in-scope frameworks identified; showing 3.

EU Medical Device Regulation — Assessment Required

Essity's Health & Medical business area includes Medical Solutions (8% of net sales) and Incontinence Products Health Care (12% of net sales), which include wound care, compression therapy, and other medical devices sold across the EU. EU MDR 2017/745 replaced the Medical Device Directive (MDD 93/42/EEC) and imposes significantly stricter requirements on medical device manufacturers, including clinical evaluation, post-market surveillance, Unique Device Identification (UDI), and registration in the EUDAMED database. Non-compliance can result in market withdrawal, regulatory sanctions, and significant reputational damage. The risk is High because medical device regulation is strictly enforced across EU member states, and the transition from MDD to MDR has been challenging for many manufacturers.

Evidence: https://www.essity.com/company/essitys-business-areas/health-and-medical/, https://www.essity.com/company/about-us/facts-and-figures/, https://www.essity.com/sustainability/sustainability-reporting-governance-and-data/certifications/

ISO 14001 — Compliant

Essity explicitly states on its certifications page that it uses ISO 14001 as an environmental management system, with a large number of production units certified. This is a publicly disclosed, actively maintained certification. The risk is Low because Essity has demonstrated commitment to environmental management certification and the certification is subject to regular third-party audits by accredited certification bodies.

Evidence: https://www.essity.com/sustainability/sustainability-reporting-governance-and-data/certifications/, https://www.essity.com/sustainability/reducing-our-impact-on-the-planet/, https://www.essity.com/sustainability/sustainability-reporting-governance-and-data/sustainability-governance/

ISO 27001 (source) — Assessment Required

ISO 27001 is not legally mandatory but is a critical information security framework for a company of Essity's scale and profile. Essity processes sensitive health data (incontinence, medical solutions), operates digital health platforms (TENA SmartCare), manages global supply chains across ~150 countries, and is subject to NIS2 cybersecurity requirements. The absence of publicly disclosed ISO 27001 certification is a significant gap for a company of this size and sector. NIS2 Article 21 requires cybersecurity risk management measures that align closely with ISO 27001 controls. Without ISO 27001 or equivalent certification, Essity's ability to demonstrate NIS2 compliance and meet enterprise customer security requirements is materially weakened. The risk is High because: (1) Essity processes special category health data requiring robust information security; (2) NIS2 compliance likely requires ISO 27001-equivalent controls; (3) cyber incidents in the healthcare/manufacturing sector are increasingly common and costly; (4) no public evidence of any information security management certification was found.

Evidence: https://www.essity.com/sustainability/sustainability-reporting-governance-and-data/certifications/, https://www.essity.com/company/about-us/facts-and-figures/, https://www.essity.com/innovation-at-essity/digitalization/

Financials

Three-year financials

Financial Resilience Score: 8/10

Essity demonstrates strong financial resilience underpinned by market-leading positions in defensive hygiene and health categories, a solid investment-grade balance sheet (Baa1/BBB+), and robust cash generation. Net debt/EBITDA excl. IAC has improved dramatically from 3.33 in 2022 to just 1.03 in 2025, reflecting deleveraging supported by the Vinda divestment proceeds (~SEK 19bn) and consistent operating cash flow (SEK 15bn in 2025). The company achieved its highest EBITA margin excl. IAC in five years (14.1%) despite headwinds, and maintains a consistent dividend growth track record (SEK 7.25 to 8.75 over 2022-2025). The business benefits from category resilience with relatively inelastic demand for hygiene and health products, supported by demographic tailwinds (aging populations), rising hygiene awareness, and emerging market penetration. Diversification is a key strength: operations in ~150 countries, with the largest single country (USA) representing just 14% of sales, top 10 customers ~25% of sales, and the largest single customer only ~4.6%. Market leadership positions (#1 or #2 in ~90% of branded sales; global #1 in incontinence via TENA and professional hygiene via Tork) provide pricing power. However, resilience is tempered by significant currency exposure (SEK strengthening cost ~SEK 8.4bn of sales in 2025), raw material volatility (pulp, recovered paper, oil-based inputs comprising ~35% of costs), energy cost exposure, and geopolitical/trade risks including US tariff impacts on 2025 gross margin. The reorganization effective January 2026 and SEK 1bn cost savings program indicate management's proactive response to margin pressures.

Key strengths: Market leadership: #1 or #2 in ~90% of branded sales globally, Strong balance sheet with net debt/EBITDA of 1.03 (down from 3.33 in 2022), Investment grade ratings: Baa1 (Moody's), BBB+ (S&P), Diversified geographic footprint across ~150 countries, Low customer concentration (top 10 = ~25%, largest = 4.6%), Robust operating cash flow of SEK 15bn in 2025, Defensive product categories with inelastic demand, Consistent dividend growth (+21% since 2022), Highest EBITA margin excl. IAC in five years (14.1%), Sustainability leadership (DJSI, CDP A-list, MSCI AAA)

Risk factors: Significant currency exposure (SEK 8.4bn negative FX impact in 2025), Raw material volatility (pulp, recovered paper, plastics ~35% of costs), Energy cost exposure (~5% of Group costs, higher in Tissue), US tariff impacts on cost of goods sold, Retail customer consolidation pressuring pricing, Declining birth rates affecting Baby Care segment, Weaker hotel/restaurant demand affecting Professional Hygiene, Increasing EU regulations on single-use products, Legal disputes related to Vinda divestment (withdrawn Jan 2026), Geopolitical/trade risks

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report